[Can cough peak flow be used to assess cough capacity in severe obstructive respiratory diseases?] / ¿Se puede utilizar la determinación del pico flujo de tos para valorar la capacidad tusígena en enfermedades respiratorias obstructivas graves?

INTRODUCTION: Cough capacity is assessed by measuring cough peak flow (CPF). However, this assessment could be altered by obstructive airway diseases. The aim was to assess measurement of cough capacity by CPF in patients with chronic obstructive pulmonary disease (COPD), as well as correlations with pulmonary, respiratory muscle, and oropharyngeal function. METHODS: Patients with COPD, and with neuromuscular disease, were selected as well as healthy subjects who had undergone respiratory muscle strength measurement in a healthcare setting. From this population, respiratory function values and lung and oropharyngeal muscle function were analysed. A subgroup of COPD patients underwent a videofluoroscopic swallow study. RESULTS: Three hundred and seven subjects were included (59.3% COPD, 38.4% neuromuscular diseases, and 2.3% healthy). CPF was found to be statistically significantly decreased in the COPD group compared to both the healthy and neuromuscular disease groups. Of the COPD patients, 70% had a pathological decrease in CPF. There was only a direct correlation between CPF with the degree of bronchial obstruction and expiratory muscle strength. No alteration of inspiratory or oropharyngeal muscle function was found. CONCLUSIONS: The use of CPF in COPD patients does not reflect cough capacity as it is influenced by the degree of bronchial obstruction. Therefore, new diagnostic tests to measure cough capacity should be considered, especially in patients with coexisting neuromuscular diseases and severe bronchial obstructive disease.

[Effects of high frequency chest wall oscillatory (HFCWO) therapy on gas exchange and ventilation in healthy participants]. / Efectos en población sana de la terapia con oscilación de alta frecuencia sobre la pared torácica (HFCWO) a nivel de la dinámica de gases pulmonares y de la mecánica respiratoria.

INTRODUCTION: Chest physiotherapy is an essential part of the treatment of respiratory diseases with increased respiratory secretion and ineffective cough. To date, there have been no studies on the effect of high frequency chest wall oscillatory (HFCWO) therapy on respiratory muscle strength, ventilation and gas exchange. The aim of this study was therefore to assess these three factors in healthy participants. METHODS: Respiratory muscle strength was measured before and immediately after HFCWO therapy in 25 healthy participants. During the treatment, we continuously measured ventilation parameters, gas exchange, oxygen saturation and heart rate. All participants underwent HFCWO sessions twice (with 24hours difference) with the same procedure. Symptoms during the session and discomfort were measured with the visual analog scale (VAS). RESULTS: HFCWO therapy produced a change in breathing pattern with increased ventilation associated with altered gas exchange. Heart rate also increased, with no changes in oxygenation. There was no effect, either beneficial or deleterious, on the strength of respiratory muscles. Up to 20% of participants reported substantial discomfort (VAS≥5/10) during the session. CONCLUSIONS: This study shows that, during the application of HFCWO therapy in healthy participants, ventilation and heart rate increased. However, there were undesirable effects on gas exchange with a high degree of intolerance among volunteers, with no effects on respiratory muscle strength.

Manejo de secreciones no invasivo en un paciente con Esclerosis Lateral Amiotrófica no colaborador, ¿dónde está el límite? A propósito de un caso / Non invasive mucus drainage in a non-collaborate Amyotrophic Lateral Sclerosis patient. Where the limit is? A case report

Las complicaciones respiratorias son una de las causas de hospitalización más frecuente, e incluso de muerte, en pacientes con enfermedad neuromuscular. El seguimiento multidisciplinar tiene efectos positivos sobre la supervivencia y la calidad de vida en estos pacientes. Este caso supuso un reto terapéutico para el manejo de secreciones bronquiales, por ser un paciente con Esclerosis Lateral Amiotrófica no colaborador y que rechazaba las medidas invasivas. Tras un primer intento fallido de adaptación al sistema mecánico de tos convencional, se modificó la interfase usando una boquilla de tipo buzo invertida, introducida entre los dientes durante la aplicación del equipo con mascarilla nasobucal. Se consiguieron muestras de esputo, lo que nos permitió tratar las infecciones respiratorias con el antibiótico específico. Además, el seguimiento se realizó por videollamada, sin necesidad de desplazar al paciente hasta el hospital. El equipo multidisciplinar se adaptó a las necesidades del paciente tratando de forma novedosa y eficaz las infecciones respiratorias. Además, el uso de nuevas tecnologías evitó ingresos hospitalarios, a pesar de ser un paciente gran dependiente.(AU)

Respiratory complications are one of the most frequent causes of hospitalization and even death in patients with neuromuscular diseases. Multidisciplinary follow-up has been shown to have positive effects on survival and quality of life in these patients. The present case represented a therapeutic challenge in order to manage respiratory secretions in a non-collaborate Amyotrophic Lateral Sclerosis patient due to the negative to accept invasive strategies to cope with respiratory infections. Despite a first failed approach in the adaptation to a mechanical assisted cough device, then a modification in the interfase allowed to mobilize secretions and it was also possible to analyze them and use the correct antibiotic treatment. Moreover, a remotely follow-up was done to handle situations, like respiratory tract infections, whenever possible, without requesting the patient to move to the hospital. The multidisciplinary unit team adapted to his needs offering a newest and efficacy strategy to cope with respiratory infections. Indeed, the use of new technologies avoided in a high dependent patient to require hospitalizations.(AU)

¿Se puede utilizar la determinación del pico flujo de tos para valorar la capacidad tusígena en enfermedades respiratorias obstructivas graves? / Can cough peak flow be used to assess cough capacity in severe obstructive respiratory diseases?

Introducción: La valoración de la capacidad tusígena se realiza con la medición del flujo espiratorio máximo durante la tos (peak-flow tos [PFT]). Sin embargo, esta valoración podría alterarse por enfermedades con obstrucción espiratoria de la vía aérea. El objetivo fue valorar la medición de la capacidad tusígena mediante PFT en pacientes con enfermedad pulmonar obstructiva crónica (EPOC), así como las correlaciones con la función pulmonar, muscular respiratoria y orofaríngea. Métodos: Se seleccionaron los pacientes con EPOC y con enfermedad neuromuscular, así como los sujetos sanos a los que se había realizado una medición de la fuerza de los músculos respiratorios de forma asistencial. De esta población, se analizaron los valores de la función respiratoria, así como la fuerza muscular orofaríngea. En un subgrupo de pacientes con EPOC se realizó el estudio de deglución por videofluoroscopia. Resultados: Se incluyeron 307 sujetos (59,3% EPOC, 38,4% enfermedades neuromusculares y 2,3% sanos). En el grupo EPOC, el PFT se encontraba disminuido de forma estadísticamente significativa comparado tanto con el grupo de los sanos como con los enfermos neuromusculares. El 70% de los EPOC tenían una disminución patológica del PFT. Solamente, existía una correlación directa entre el PFT con el grado de obstrucción bronquial y la fuerza de los músculos espiratorios. No se encontró alteración de la función de los músculos inspiratorios ni orofaríngeos. Conclusiones: La utilización del PFT en los pacientes con EPOC no refleja la capacidad tusígena ya que se ve influenciada por el grado de obstrucción bronquial. Por tanto, se deberían valorar nuevas pruebas diagnósticas para la medición de la capacidad tusígena, fundamentalmente, en los pacientes que coexistan enfermedades neuromusculares y patología obstructiva bronquial grave.(AU)

Introduction: Cough capacity is assessed by measuring cough peak flow (CPF). However, this assessment could be altered by obstructive airway diseases. The aim was to assess measurement of cough capacity by CPF in patients with chronic obstructive pulmonary disease (COPD), as well as correlations with pulmonary, respiratory muscle, and oropharyngeal function. Methods: Patients with COPD, and with neuromuscular disease, were selected as well as healthy subjects who had undergone respiratory muscle strength measurement in a healthcare setting. From this population, respiratory function values and lung and oropharyngeal muscle function were analysed. A subgroup of COPD patients underwent a videofluoroscopic swallow study. Results: Three hundred and seven subjects were included (59.3% COPD, 38.4% neuromuscular diseases, and 2.3% healthy). CPF was found to be statistically significantly decreased in the COPD group compared to both the healthy and neuromuscular disease groups. Of the COPD patients, 70% had a pathological decrease in CPF. There was only a direct correlation between CPF with the degree of bronchial obstruction and expiratory muscle strength. No alteration of inspiratory or oropharyngeal muscle function was found. Conclusions: The use of CPF in COPD patients does not reflect cough capacity as it is influenced by the degree of bronchial obstruction. Therefore, new diagnostic tests to measure cough capacity should be considered, especially in patients with coexisting neuromuscular diseases and severe bronchial obstructive disease.(AU)

Efectos en población sana de la terapia con oscilación de alta frecuencia sobre la pared torácica (HFCWO) a nivel de la dinámica de gases pulmonares y de la mecánica respiratoria / Effects of high frequency chest wall oscillatory (HFCWO) therapy on gas exchange and ventilation in healthy participants

Introducción La fisioterapia respiratoria es parte imprescindible del tratamiento de las patologías hipersecretoras o con compromiso de la capacidad tusígena. Hasta el momento se desconoce el efecto del dispositivo de terapia de oscilación de alta frecuencia en la pared torácica (HFCWO) sobre la fuerza de los músculos respiratorios y los efectos sobre la mecánica respiratoria y la dinámica de los gases respiratorios. Por ello, el objetivo de este estudio fue describir estos tres aspectos en sujetos sanos. Métodos Se midió la fuerza de los músculos respiratorios en 25 sujetos antes e inmediatamente después de terapia con HFCWO. Durante la sesión, se midieron continuamente los parámetros de ventilación, la dinámica de los gases respiratorios y la frecuencia cardiaca. Se llevaron a cabo dos sesiones idénticas por sujeto, separadas 24h. Se registraron los síntomas durante la sesión y las molestias experimentadas mediante escala analógica visual (EVA). Resultados La terapia con HFCWO produce un incremento de la ventilación asociado con una alteración de la dinámica de los gases respiratorios. También se aumenta la frecuencia cardiaca, sin modificación de la oxigenación tisular. No se observaron efectos sobre la fuerza de los músculos respiratorios. Hasta un 20% de los participantes indicó molestias importantes (EVA≥5/10) durante la sesión. Conclusiones Durante la aplicación de HFCWO en sujetos sanos se produce incremento en la ventilación y ritmo cardiaco. Sin embargo, aparecen efectos indeseables sobre la dinámica de los gases respiratorios y un grado elevado de intolerancia por parte de los voluntarios y no hay efectos sobre la fuerza de los músculos respiratorios (AU)

Introduction Chest physiotherapy is an essential part of the treatment of respiratory diseases with increased respiratory secretion and ineffective cough. To date, there have been no studies on the effect of high frequency chest wall oscillatory (HFCWO) therapy on respiratory muscle strength, ventilation and gas exchange. The aim of this study was therefore to assess these three factors in healthy participants. Methods Respiratory muscle strength was measured before and immediately after HFCWO therapy in 25 healthy participants. During the treatment, we continuously measured ventilation parameters, gas exchange, oxygen saturation and heart rate. All participants underwent HFCWO sessions twice (with 24hours difference) with the same procedure. Symptoms during the session and discomfort were measured with the visual analog scale (VAS). Results HFCWO therapy produced a change in breathing pattern with increased ventilation associated with altered gas exchange. Heart rate also increased, with no changes in oxygenation. There was no effect, either beneficial or deleterious, on the strength of respiratory muscles. Up to 20% of participants reported substantial discomfort (VAS≥5/10) during the session. Conclusions This study shows that, during the application of HFCWO therapy in healthy participants, ventilation and heart rate increased. However, there were undesirable effects on gas exchange with a high degree of intolerance among volunteers, with no effects on respiratory muscle strength (AU)